KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity

Cancer Letters

Volumn 331, Issue 2, 2013, Pages 158-166

  Park, Byung Hee ^a   Jung, Kyung Hee ^a   Yun, Sun Mi ^a   Hong, Sang Won ^a   Ryu, Jae Wook ^b   Jung, Heejung ^b   Ha, Jae Du ^b   Lee, Jongkook ^b,c   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

C Met; Cancer; HGF; KRC 327

Indexed keywords

5 [(6 PHENYL[1,2,4]TRIAZOLO[4,3 B]PYRIDAZIN 3 YL)METHYL]ISOQUINOLIN 1(2H) ONE; CYCLIN D1; KRC 327; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN; CELL STRAIN AGS; CELL STRAIN BXPC 3; CELL STRAIN MKN 1; CELL STRAIN MKN 45; CELL STRAIN SNU 1; CELL STRAIN SNU 5; CELL STRAIN SNU 638; COLONY FORMATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; ISOQUINOLINES; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDAZINES; RECEPTOR PROTEIN-TYROSINE KINASES;

ANIMALIA;

EID: 84875369050     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.025     Document Type: Article

References (28)

1. Boccaccio C., Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 2006, 6:637-645.
2. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 2008, 7:504-516.
3. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
4. Seiwert T.Y., Jagadeeswaran R., Faoro L., Janamanchi V., Nallasura V., El Dinali M., Yala S., Kanteti R., Cohen E.E., Lingen M.W., Martin L., Krishnaswamy S., Klein-Szanto A., Christensen J.G., Vokes E.E., Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009, 69:3021-3031.
5. Christensen J.G., Burrows J., Salgia R. C-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005, 225:1-26.
6. Galeazzi E., Olivero M., Gervasio F.C., De Stefani A., Valente G., Comoglio P.M., Di Renzo M.F., Cortesina G. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur. Arch. Otorhinolaryngol. 1997, 254(Suppl. 1):S138-143.
7. Liu X., Yao W., Newton R.C., Scherle P.A. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin. Investig. Drugs 2008, 17:997-1011.
8. Zeng Z.S., Weiser M.R., Kuntz E., Chen C.T., Khan S.A., Forslund A., Nash G.M., Gimbel M., Yamaguchi Y., Culliford A.T.t., D'Alessio M., Barany F., Paty P.B. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008, 265:258-269.
9. Liu X., Newton R.C., Scherle P.A. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol. Med. 2010, 16:37-45.
10. Ryu J.W., Han S.Y., Yun J.I., Choi S.U., Jung H., Ha J.D., Cho S.Y., Lee C.O., Kang N.S., Koh J.S., Kim H.R., Lee J. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors. Bioorg. Med. Chem. Lett. 2011, 21:7185-7188.
11. Diao Y., Ma D., Wen Z., Yin J., Xiang J., Li M. Using pseudo amino acid composition to predict transmembrane regions in protein: cellular automata and Lempel-Ziv complexity. Amino Acids 2008, 34:111-117.
12. Albrecht B.K., Harmange J.C., Bauer D., Berry L., Bode C., Boezio A.A., Chen A., Choquette D., Dussault I., Fridrich C., Hirai S., Hoffman D., Larrow J.F., Kaplan-Lefko P., Lin J., Lohman J., Long A.M., Moriguchi J., O'Connor A., Potashman M.H., Reese M., Rex K., Siegmund A., Shah K., Shimanovich R., Springer S.K., Teffera Y., Yang Y., Zhang Y., Bellon S.F. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J. Med. Chem. 2008, 51:2879-2882.
13. Ma W.W., Adjei A.A. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 2009, 59:111-137.
14. Al-Obeidi F.A., Lam K.S. Development of inhibitors for protein tyrosine kinases. Oncogene 2000, 19:5690-5701.
15. Weidner K.M., Di Cesare S., Sachs M., Brinkmann V., Behrens J., Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996, 384:173-176.
16. Khwaja A., Lehmann K., Marte B.M., Downward J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 1998, 273:18793-18801.
17. Potempa S., Ridley A.J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 1998, 9:2185-2200.
18. Xiao G.H., Jeffers M., Bellacosa A., Mitsuuchi Y., Vande Woude G.F., Testa J.R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. USA 2001, 98:247-252.
19. Comoglio P.M. Pathway specificity for Met signalling. Nat. Cell Biol. 2001, 3:E161-E$162.
20. Furge K.A., Zhang Y.W., Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000, 19:5582-5589.
21. Wong A.S., Roskelley C.D., Pelech S., Miller D., Leung P.C., Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp. Cell Res. 2004, 299:248-256.
22. Wong A.S., Pelech S.L., Woo M.M., Yim G., Rosen B., Ehlen T., Leung P.C., Auersperg N. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?. Oncogene 2001, 20:1318-1328.
23. Royal I., Fournier T.M., Park M. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis. J. Cell. Physiol. 1997, 173:196-201.
24. Pietenpol J.A., Stewart Z.A. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 2002, 181-182:475-481.
25. Malumbres M., Pevarello P., Barbacid M., Bischoff J.R. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol. Sci. 2008, 29:16-21.
26. Yoon M.K., Mitrea D.M., Ou L., Kriwacki R.W. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem. Soc. Trans. 2012, 40:981-988.
27. Tateishi Y., Matsumoto A., Kanie T., Hara E., Nakayama K., Nakayama K.I. Development of mice without Cip/Kip CDK inhibitors. Biochem. Biophys. Res. Commun. 2012.
28. Que W., Chen J., Chuang M., Jiang D. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS 2012, 120:195-203.